A Study of LY3434172, a PD-1 and PD-L1 Bispecific Antibody, in Advanced Cancer

NCT03936959 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

10

Enrollment

INDUSTRY

Sponsor class

Stopped Study did not achieve its primary objective due to early termination of the study

Conditions

Advanced Cancer

Interventions

DRUG: LY3434172

Sponsor

Eli Lilly and Company